|
MechanismIL-2Rβγ agonists |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1/2, Dose-Escalation and Cohort-Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of LAT010 in Patients with Advanced Solid Tumors (LIGHTSPEED-1)
This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and cohort-expansion study of LAT010 to evaluate the safety, tolerability, immunogenicity, PK, PD, and antitumor activity in patients with advanced solid tumors. The study consists of 2 parts: Phase 1 dose-escalation and Phase 2 cohort expansion.
100 Clinical Results associated with Latticon Antibody Therapeutics, Inc
0 Patents (Medical) associated with Latticon Antibody Therapeutics, Inc
100 Deals associated with Latticon Antibody Therapeutics, Inc
100 Translational Medicine associated with Latticon Antibody Therapeutics, Inc